Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 References  














NS-11394






Српски / srpski
Srpskohrvatski / српскохрватски
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


NS-11394
Identifiers
  • 2-(3-[5-(2-hydroxypropan-2-yl)benzimidazol-1-yl]phenyl)benzonitrile

CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H19N3O
Molar mass353.425 g·mol−1
3D model (JSmol)
  • N#Cc2ccccc2-c(ccc3)cc3-n1cnc(c4)c1ccc4C(C)(C)O

  • InChI=1S/C23H19N3O/c1-23(2,27)18-10-11-22-21(13-18)25-15-26(22)19-8-5-7-16(12-19)20-9-4-3-6-17(20)14-24/h3-13,15,27H,1-2H3 ☒N

  • Key:HLKYSQGBIIIQJN-UHFFFAOYSA-N ☒N

 ☒NcheckY (what is this?)  (verify)

NS-11394 is a drug which acts as a subtype-selective positive allosteric modulatoratGABAA receptors, with selectivity for the α3 and α5 subtypes.[1][2] It has been researched as an analgesic for use in chronic or neuropathic pain.[3]

References[edit]

  1. ^ Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen EØ, Larsen JS, Ahring PK, Mirza NR (December 2008). "Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 969–81. doi:10.1124/jpet.108.144568. PMID 18791060. S2CID 36490884.
  • ^ Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen EØ, Ahring PK (December 2008). "NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 954–68. doi:10.1124/jpet.108.138859. PMID 18791063. S2CID 206499795.
  • ^ Munro G, Ahring PK, Mirza NR (September 2009). "Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets". Trends in Pharmacological Sciences. 30 (9): 453–9. doi:10.1016/j.tips.2009.06.004. PMID 19729210.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=NS-11394&oldid=1120163806"

    Categories: 
    Analgesics
    GABAA receptor positive allosteric modulators
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Articles with changed ChemSpider identifier
    Articles with changed InChI identifier
    Articles without EBI source
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Drugs missing an ATC code
    Drugs with no legal status
    Drugboxes which contain changes to verified fields
     



    This page was last edited on 5 November 2022, at 14:11 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki